公开(公告)号：EP3251675A4

公开(公告)日：2018-06-20

申请号：EP16742632

申请日：2016-01-28

申请人： SHANTON PHARMA CO LTD

发明人： ZHANG QIAN ,  HUANG ZHENHUA ,  LIU JINRONG ,  CHI SHUANGSHUANG

IPC分类号： C07D473/08 ,  A61K31/522 ,  A61P13/04 ,  A61P13/12 ,  A61P19/02 ,  A61P19/06 ,  A61P29/00 ,  C07D473/06

CPC分类号： A61K31/522 ,  A61K31/4188 ,  A61K2300/00 ,  C07D473/04 ,  C07D473/06 ,  C07D473/08 ,  C07D487/04

摘要： The present invention relates to the use of a compound of formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, or a pharmaceutical composition containing the same in reducing uric acid level, preventing or reducing inflammations, and preventing or treating uratic or gouty diseases. In particular, the present invention relates to the use of a compound of formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, or a pharmaceutical composition containing the same in the manufacture of a medicament for the treatment or prevention of hyperuricemia, gout, gouty inflammations, pain and uric acid nephropathy. R 1 represents hydrogen, C 1-4 alkyl or the like. R 2 represents C 1-10 alkyl or the like. R 3 represents halogen or the like.